13F HOLDINGS REPORT
Foresite Capital Management VI LLC
Quarter ended Q4 2024 · Filed February 14, 2025 · Accession 0001104659-25-013964
Total Value
$224.4M
Positions
14
Other Managers
0
Confidential Omitted
No
Holdings (14)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG Oncology, Inc. | CGON | 2,221,474 | $63.7M | 28.39% |
| 2 | Alumis Inc | ALMS | 4,202,670 | $33.0M | 14.72% |
| 3 | Centessa Pharmaceuticals Inc | CNTA | 1,253,379 | $21.0M | 9.35% |
| 4 | Rapt Therapeutics Inc | 75382E109 | 12,500,000 | $19.8M | 8.80% |
| 5 | Bicara Therapeutics Inc | BCAX | 950,000 | $16.5M | 7.37% |
| 6 | Edgewise Therapeutics Inc | EWTX | 585,000 | $15.6M | 6.96% |
| 7 | Structure Therapeutics Inc | GPCR | 420,000 | $11.4M | 5.08% |
| 8 | Akero Therapeutics Inc | 00973Y108 | 365,000 | $10.2M | 4.52% |
| 9 | Corvus Pharmaceuticals Inc | CRVS | 1,581,233 | $8.5M | 3.77% |
| 10 | Cullinan Therapeutics Inc | CGEM | 634,558 | $7.7M | 3.44% |
| 11 | Allogene Therapeutics Inc | ALLO | 3,448,275 | $7.3M | 3.27% |
| 12 | Kymera Therapeutics Inc | KYMR | 146,332 | $5.9M | 2.62% |
| 13 | Casi Pharmaceuticals Inc | CASIF | 1,329,383 | $3.8M | 1.68% |
| 14 | Viridian Therapeutics, Inc | VRDN | 1,974 | $37,842 | 0.02% |